Synthego has expanded its CRISPR solutions portfolio with the launch of GMP SpCas9, offering researchers a powerful solution to enhance CRISPR-based therapeutic development. The launch of GMP SpCas9 enables researchers to bundle the nuclease with IND-enabling or GMP sgRNAs into a convenient, unified package, optimizing processes and driving therapeutic progress..

Synthego通过推出GMP SpCas9扩展了其CRISPR解决方案组合，为研究人员提供了增强基于CRISPR的治疗开发的强大工具。GMP SpCas9的推出使研究人员能够将该核酸酶与IND支持或GMP sgRNA打包成一个便捷的统一方案，优化流程并推动治疗进展。

Produced under certified cGMP manufacturing standards, GMP SpCas9, in combination with best-in-class GMP sgRNAs, provides researchers with a comprehensive CRISPR solution that ensures exceptional quality, consistency, and scalability required for therapeutic applications. Further supporting development, Synthego offers access to Drug Master Files (DMFs) with unified regulatory documentation for both GMP sgRNAs and GMP SpCas9, simplifying regulatory submission filings and reducing complexity..

在经过认证的cGMP生产标准下生产的GMP SpCas9，与一流的GMP sgRNA结合，为研究人员提供了全面的CRISPR解决方案，确保了治疗应用所需的卓越质量、一致性和可扩展性。为进一步支持开发，Synthego提供对药物主文件（DMFs）的访问，其中包含GMP sgRNA和GMP SpCas9的统一监管文档，简化了监管提交流程并降低了复杂性。

'We are excited to expand our portfolio of best-in-class CRISPR solutions to include a GMP SpCas9 nuclease. With this addition, we now provide the highest quality CRISPR-based gene editing tools desired for human clinical studies, at a budget-friendly price. It is our continuing mission to democratize CRISPR at both the academic and clinical research phase without compromising on quality,' said Jason Miller, Chief Commercial Officer..

“我们很高兴扩展我们的一流CRISPR解决方案组合，新增GMP SpCas9核酸酶。通过这一补充，我们现在以实惠的价格提供适用于人类临床研究的最高质量CRISPR基因编辑工具。我们持续的使命是在学术和临床研究阶段普及CRISPR，同时不妥协于质量。”首席商务官Jason Miller表示。

Through the launch of GMP SpCas9 and its seamless integration with GMP sgRNAs, Synthego continues to deliver cutting-edge CRISPR solutions that empower therapeutic developers to accelerate progress in CRISPR-based cell and gene therapies. Discover more about GMP SpCas9 and GMP sgRNAs by visiting the product page or contacting our experts to start your GMP project..

通过推出GMP SpCas9并将其与GMP sgRNA无缝整合，Synthego持续提供前沿的CRISPR解决方案，助力治疗开发者加速基于CRISPR的细胞和基因疗法的进展。访问产品页面或联系我们的专家，了解更多关于GMP SpCas9和GMP sgRNA的信息，启动您的GMP项目。

About Synthego

关于Synthego

Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health. By providing unparalleled access to CRISPR solutions at scale, Synthego enables agility in life science discovery and clinical advancement.

Synthego是生物技术领域的领导者，致力于提供一流的CRISPR解决方案，其使命是加速研发进程，以追求改善人类健康。通过大规模提供无与伦比的CRISPR解决方案访问权限，Synthego为生命科学发现和临床进展提供了灵活性。

With streamlined licensing models and exceptional technical expertise, Synthego empowers researchers and developers to unlock better patient outcomes through innovative CRISPR cell and gene therapies..

通过简化的许可模式和卓越的技术专长，Synthego 赋予研究人员和开发人员通过创新的 CRISPR 细胞和基因疗法解锁更好的患者结果的能力。

Source: prnewswire.com

来源：prnewswire.com